Date: 2016-04-19
Type of information: Opening of new premises
Compound:
Company: MRC Technology (UK)
Therapeutic area:
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On April 19, 2016, MRC Technology, an independent life science medical research charity, has completed the move of its Centre for Therapeutics Discovery to state-of-the-art laboratory facilities at the Stevenage Bioscience Catalyst (SBC) campus. Some teams will also relocate from the central London office. The charity will still have an office in London, along with laboratories and an office in Edinburgh. The move marks the next stage in MRC Technology’s mission to be a catalyst for life changing science, improving human health and advancing medical research. Through the open innovation network of the SBC campus, MRC Technology will have access to increased opportunities to collaborate with industry, charities, universities and health organisations to speed up life science discovery and translation processes.
From its inception in 2000, MRC Technology projects have led to 12 drugs on the market including Tysabri®, Actemra®, Entyvio® and Keytruda®. Research partnerships have been formed with over 40 universities and academic institutes, and alliances with 20 medical research charities. MRC Technology has generated over £630M in royalty income for research partners, enabling them to fund additional research.
Financial terms:
Latest news:
